Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Dr. Gaurav Shah is the Chief Executive Officer of Rocket Pharmaceuticals Inc, joining the firm since 2018.
What is the price performance of RCKT stock?
The current price of RCKT is $3.61, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Rocket Pharmaceuticals Inc?
Rocket Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Rocket Pharmaceuticals Inc market cap?
Rocket Pharmaceuticals Inc's current market cap is $394.4M
Is Rocket Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Rocket Pharmaceuticals Inc, including 5 strong buy, 7 buy, 7 hold, 2 sell, and 5 strong sell